Albert Jean Robichaud

Ringoes, NJ, United States of America

Albert Jean Robichaud

Average Co-Inventor Count = 4.4

ph-index = 22

Forward Citations = 1,968(Granted Patents)

Forward Citations (Not Self Cited) = 1,209(Sep 21, 2024)

DiyaCoin DiyaCoin 2.49 

Inventors with similar research interests:


Location History:

  • Ladenberg, PA (US) (2004)
  • Landenberg, PA (US) (2003 - 2007)
  • Ringoes, NJ (US) (2005 - 2019)
  • Cambridge, MA (US) (2018 - 2021)
  • Boston, MA (US) (2020 - 2024)


Years Active: 2003-2025

where 'Filed Patents' based on already Granted Patents

103 patents (USPTO):
14 patents (CIPO):

Title: The Innovative Journey of Inventor Albert Jean Robichaud

Introduction:

Albert Jean Robichaud, a prolific inventor based in Ringoes, NJ, has left a significant mark in the field of CNS disorder treatment with his groundbreaking patents.

Latest Patents:

Albert Jean Robichaud's latest patents include compositions and methods for treating CNS disorders. These patents focus on neuroactive steroids and C7 substituted oxysterols, which have shown promise as GABA modulators and for the prevention and treatment of various conditions.

Career Highlights:

With an impressive portfolio of 92 patents, Albert Jean Robichaud has demonstrated his expertise and commitment to advancing pharmaceutical innovations. He has made significant contributions to companies such as Sage Therapeutics, Inc. and Wyeth, where his innovative research has paved the way for novel treatment methods.

Collaborations:

Throughout his career, Albert Jean Robichaud has collaborated with esteemed professionals in the field, including Francesco Gerald Salituro and Gabriel Martinez Botella. These collaborations have enriched his research endeavors and led to impactful developments in the field of CNS disorder treatment.

Conclusion:

Albert Jean Robichaud's relentless pursuit of innovation and dedication to improving healthcare outcomes through his patented inventions exemplify his status as a visionary inventor. His contributions continue to inspire advancements in the pharmaceutical industry, shaping the future of CNS disorder treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…